Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF posts a operating income of $510M as of June 2026. That compares with $520M in the prior-year period — down 3.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's operating income was $520M. The latest reading is $510M — a 3.6% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's financial statement story. At $510M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GERM's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's other metric pages and overview cover the third.